This week's Lab Notes has items on a $37 million agreement between a cell therapy developer and a Big Pharma company, a $5 million equity financing deal, the sudden loss of a Bucks County biopharmaceutical company's chief medical officer and more.
Here's the roundup:
AdaptImmune Therapeutics
The T-cell therapy company with operations in Philadelphia and Oxford, England, has entered into a "transition agreement" with GlaxoSmithKline under which Adaptimmune will get back the rights and materials…
